Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Vanflyta (quizartinib dihydrochloride) — Daiichi Sankyo Europe GmbH
Vanflyta (quizartinib dihydrochloride) has been authorised in Europe for leukemia/myeloid indications.
-
EMA approval · 2026-07-17EMA Authorised: Inaqovi (cedazuridine;decitabine) — Otsuka Pharmaceutical Netherlands B.V.
EMA has authorised Inaqovi (cedazuridine/decitabine) for leukemias with myeloid involvement, expanding available treatment options.
-
EMA approval · 2026-06-25EMA Authorised: Inaqovi (cedazuridine;decitabine) — Otsuka Pharmaceutical Netherlands B.V.
EMA has authorised Inaqovi (cedazuridine; decitabine) for use in leukemia with a myeloid therapeutic focus.
-
EMA approval · 2025-03-10EMA Authorised: Inaqovi (cedazuridine;decitabine) — Otsuka Pharmaceutical Netherlands B.V.
The European Medicines Agency authorised Inaqovi, a fixed-dose oral combination of cedazuridine and decitabine, for adult patients with myel…